Published in Hepatology on April 01, 2007
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell (2010) 2.20
The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene (2009) 1.97
Krüppel-like factor 4, a tumor suppressor in hepatocellular carcinoma cells reverts epithelial mesenchymal transition by suppressing slug expression. PLoS One (2012) 1.87
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med (2010) 1.86
Viral hepatocarcinogenesis. Oncogene (2010) 1.73
Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res (2011) 1.67
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66
Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS One (2010) 1.65
Interleukin-30: a novel antiinflammatory cytokine candidate for prevention and treatment of inflammatory cytokine-induced liver injury. Hepatology (2012) 1.62
The emerging role of CXCL10 in cancer (Review). Oncol Lett (2011) 1.54
The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int (2012) 1.53
Differential network entropy reveals cancer system hallmarks. Sci Rep (2012) 1.52
UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. Cancer Cell (2014) 1.50
Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res (2009) 1.50
Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res (2009) 1.45
Integrative analysis of multi-omics data for identifying multi-markers for diagnosing pancreatic cancer. BMC Genomics (2015) 1.44
Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin (2010) 1.40
Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips. Epigenetics (2012) 1.39
De-regulation of common housekeeping genes in hepatocellular carcinoma. BMC Genomics (2007) 1.39
Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology (2013) 1.27
High-throughput assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCV-associated hepatocellular carcinoma. Mol Genet Genomics (2010) 1.27
Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol (2008) 1.26
Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limiting. PLoS One (2011) 1.26
Increased cell migration and plasticity in Nrf2-deficient cancer cell lines. Oncogene (2010) 1.26
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol (2012) 1.26
Reconstruction of genome-scale metabolic models for 126 human tissues using mCADRE. BMC Syst Biol (2012) 1.24
Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5'TOP mRNA translation. Genes Dev (2014) 1.22
Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology (2008) 1.21
Identifying critical transitions and their leading biomolecular networks in complex diseases. Sci Rep (2012) 1.17
Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget (2014) 1.14
Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models. Cancer Cell (2014) 1.13
A high level of liver-specific expression of oncogenic Kras(V12) drives robust liver tumorigenesis in transgenic zebrafish. Dis Model Mech (2011) 1.13
Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics (2012) 1.10
Protein kinase Cι expression and oncogenic signaling mechanisms in cancer. J Cell Physiol (2011) 1.08
Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods (2013) 1.08
GenRev: exploring functional relevance of genes in molecular networks. Genomics (2011) 1.07
Global analysis of DNA methylation in early-stage liver fibrosis. BMC Med Genomics (2012) 1.07
Exploring genomic profiles of hepatocellular carcinoma. Mol Carcinog (2011) 1.05
Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model. Nat Genet (2013) 1.04
Integrative network analysis identifies key genes and pathways in the progression of hepatitis C virus induced hepatocellular carcinoma. BMC Med Genomics (2011) 1.02
SULFs in human neoplasia: implication as progression and prognosis factors. J Transl Med (2011) 1.02
Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts. J Virol (2011) 1.00
A transgenic zebrafish liver tumor model with inducible Myc expression reveals conserved Myc signatures with mammalian liver tumors. Dis Model Mech (2012) 1.00
Regulation of integrin endocytic recycling and chemotactic cell migration by syntaxin 6 and VAMP3 interaction. J Cell Sci (2012) 0.98
Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol Med (2009) 0.97
C8orf4 negatively regulates self-renewal of liver cancer stem cells via suppression of NOTCH2 signalling. Nat Commun (2015) 0.97
Deregulated direct targets of the hepatitis B virus (HBV) protein, HBx, identified through chromatin immunoprecipitation and expression microarray profiling. J Biol Chem (2009) 0.96
Dynamic protein interaction modules in human hepatocellular carcinoma progression. BMC Syst Biol (2013) 0.96
Hepatitis C virus and hepatocarcinogenesis. Clin Mol Hepatol (2012) 0.96
PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation. Nat Commun (2015) 0.95
Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis. PLoS One (2013) 0.95
βII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology (2015) 0.95
Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy. World J Gastroenterol (2013) 0.95
The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation. Oncogene (2015) 0.95
HCV tumor promoting effect is dependent on host genetic background. PLoS One (2009) 0.95
Large-scale analysis of network bistability for human cancers. PLoS Comput Biol (2010) 0.95
Gene expression analysis in serial liver fine needle aspirates. J Viral Hepat (2014) 0.93
Xmrk, kras and myc transgenic zebrafish liver cancer models share molecular signatures with subsets of human hepatocellular carcinoma. PLoS One (2014) 0.93
Hepatitis C virus mediated changes in miRNA-449a modulates inflammatory biomarker YKL40 through components of the NOTCH signaling pathway. PLoS One (2012) 0.91
Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. J Hepatol (2013) 0.91
KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. Cancer Chemother Pharmacol (2014) 0.91
An oncogenic role of Agrin in regulating focal adhesion integrity in hepatocellular carcinoma. Nat Commun (2015) 0.91
Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transpl (2011) 0.90
Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol (2015) 0.90
A systems biology-based classifier for hepatocellular carcinoma diagnosis. PLoS One (2011) 0.90
Proteomic dissection of cell type-specific H2AX-interacting protein complex associated with hepatocellular carcinoma. J Proteome Res (2010) 0.90
TLRs, Alcohol, HCV, and Tumorigenesis. Gastroenterol Res Pract (2011) 0.88
Affinity capture and identification of host cell factors associated with hepatitis C virus (+) strand subgenomic RNA. Mol Cell Proteomics (2013) 0.88
Comprehensive functional characterization of cancer-testis antigens defines obligate participation in multiple hallmarks of cancer. Nat Commun (2015) 0.87
Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old. Mol Cancer (2010) 0.87
Centrosomal kinase Nek2 cooperates with oncogenic pathways to promote metastasis. Oncogenesis (2013) 0.87
Identifying genes for establishing a multigenic test for hepatocellular carcinoma surveillance in hepatitis C virus-positive cirrhotic patients. Cancer Epidemiol Biomarkers Prev (2009) 0.86
An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer. Cancer Res (2012) 0.86
Reconstructing dynamic gene regulatory networks from sample-based transcriptional data. Nucleic Acids Res (2012) 0.86
Turning hepatic cancer stem cells inside out--a deeper understanding through multiple perspectives. Mol Cells (2015) 0.86
Profiling of exome mutations associated with progression of HBV-related hepatocellular carcinoma. PLoS One (2014) 0.86
Functional and topological properties in hepatocellular carcinoma transcriptome. PLoS One (2012) 0.86
Long non-coding RNA expression profiles of hepatitis C virus-related dysplasia and hepatocellular carcinoma. Oncotarget (2015) 0.85
Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol (2015) 0.85
Meta-analysis of the expression of the mitosis-related gene Fam83D. Oncol Lett (2012) 0.85
REGγ is associated with multiple oncogenic pathways in human cancers. BMC Cancer (2012) 0.84
Hec1/Ndc80 is overexpressed in human gastric cancer and regulates cell growth. J Gastroenterol (2013) 0.84
Watch the GAP: Emerging Roles for IQ Motif-Containing GTPase-Activating Proteins IQGAPs in Hepatocellular Carcinoma. Int J Hepatol (2012) 0.84
Gene expression profile analysis of human hepatocellular carcinoma using SAGE and LongSAGE. BMC Med Genomics (2009) 0.84
The La-related protein 1-specific domain repurposes HEAT-like repeats to directly bind a 5'TOP sequence. Nucleic Acids Res (2015) 0.83
Comparison of gene expression in hepatocellular carcinoma, liver development, and liver regeneration. Mol Genet Genomics (2010) 0.83
Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer. PLoS One (2013) 0.83
ZIC2-dependent OCT4 activation drives self-renewal of human liver cancer stem cells. J Clin Invest (2015) 0.83
Microarray-based gene expression analysis of hepatocellular carcinoma. Curr Genomics (2010) 0.83
Retinoblastoma protein potentiates the innate immune response in hepatocytes: significance for hepatocellular carcinoma. Hepatology (2014) 0.82
TGF-β signaling is often attenuated during hepatotumorigenesis, but is retained for the malignancy of hepatocellular carcinoma cells. PLoS One (2013) 0.82
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Hepatocellular carcinoma. Lancet (2003) 22.54
Hepatocellular carcinoma. Lancet (2012) 18.09
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis (2010) 5.85
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17
Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05
Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol (2013) 4.28
miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
Mechanisms of action of arsenic trioxide. Cancer Res (2002) 3.68
Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology (2015) 3.63
CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest (2009) 3.62
Focus on hepatocellular carcinoma. Cancer Cell (2004) 3.49
Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int (2012) 3.46
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2012) 3.39
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Management of HCC. J Hepatol (2012) 3.03
Chemoembolization for hepatocellular carcinoma. Gastroenterology (2004) 2.89
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79
New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology (2013) 2.76
Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol (2008) 2.74
Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70
Three-year efficacy and acceptability of the GyneFix 200 intrauterine system. Contraception (2004) 2.69
Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology (2010) 2.68
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2004) 2.67
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl (2004) 2.65
Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology (2010) 2.61
Differential gene expression following early renal ischemia/reperfusion. Kidney Int (2003) 2.60
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood (2007) 2.58
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology (2004) 2.54
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol (2012) 2.53
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42